SOUTH EASTON, Mass., Sept. 11 PressureBioSciences, Inc. (Nasdaq: PBIO) ("PBI" or "the Company") today announced thatit has entered into a Cooperative Research and Development Agreement (CRADA)with the United States Army Medical Research Institute of Infectious Diseases(USAMRIID). Researchers at USAMRIID have recently shown that the use of theCompany's patented pressure cycling technology ("PCT") with patent-pendingchemical reagents ("ProteoSolve-SB") has resulted in the simultaneousdecontamination and extraction of macromolecules (DNA, RNA, proteins, lipids)as well as small molecules from samples containing infectious pathogens. Thepurpose of this CRADA is to adapt PCT into protocols for the development ofmedical countermeasures against dangerous pathogens that endanger thewarfighter. The CRADA will allow scientists from PBI and USAMRIID to combineresources, experiences, and expertise to help achieve this important goal.
Dr. Chunquin Li, Applications Scientist for Pressure BioSciences, said:"The decontamination and extraction of biomolecules from samples containingdangerous infectious pathogens for subsequent analysis is essential to thedevelopment of improved therapies, vaccines, and diagnostics needed to protectsoldiers, emergency responders, and others against possible exposure tobiological threat agents."
Dr. Nathan Lawrence, Vice President of Marketing at PBI commented:"Research on dangerous pathogens takes place within specially engineeredBioSafety Level (BSL) -3 or -4 suites. A rapid procedure to completelydecontaminate macromolecules enables the transfer of samples out ofcontainment suites where further studies are more easily conducted. Whiletraditional methods for decontamination have been proven safe, they oftenrender biological samples unsuitable for modern, state-of-the-art biomolecularanalysis. Researchers at USAMRIID have demonstrated that PCT coupled withProteoSolve-SB can kill infectious agents, without significant adverse effectson the subsequent testing and analysis of macromolecules. This was animportant advancement, since some macromolecular assays cannot be readilyperformed in BSL containment. These findings warranted further testing."
Mr. Richard T. Schumacher, Founder, President, and CEO of PressureBioSciences, said: "We believe that data generated under the CRADA couldsignificantly accelerate and enhance current research studies involvinginfectious or dangerous agents. Such improvements could be of greatimportance to USAMRIID investigators, as well as to all scientists, whethermilitary or in the public or private sector, who are working to develop moreeffective tools to counter bioterrorism. In addition, the knowledge gainedfrom research performed under this CRADA may be of great importance to themany laboratories around the world working on the development of improvedmedical protections - including diagnostics, therapeutics, and vaccines -against infectious diseases not related to biological threat agents."
PBI will support the CRADA by offering USAMRIID the use of a BarocyclerNEP3229 for a mutually agreed upon period of evaluation; by supplyingconsumable processing containers (PULSE Tubes) and kits to USAMRIID; and bythe efforts of up to eight hours per week of technical support from PBIscientists. All of these items will be offered at no charge. Conversely,USAMRIID will support the CRADA through the technical support of itsscientific staff available for both containment and non-containment work.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused onthe development of a novel, enabling technology called Pressure CyclingTechnology (PCT). PCT uses cycles of hydrostatic pressure between ambient andultra-high levels (up to 35,000 psi and greater) to control bio-molecularinteractions. PBI currently holds 13 US and 6